What is HC Wainwright’s Forecast for SNDX Q1 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Syndax Pharmaceuticals in a report issued on Tuesday, March 4th. HC Wainwright analyst E. White expects that the company will post earnings per share of ($1.00) for the quarter. HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2025 earnings at ($0.98) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS and FY2027 earnings at ($1.44) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million.

Several other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday. Scotiabank reduced their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Finally, The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $36.00.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX opened at $14.48 on Wednesday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -3.99 and a beta of 0.90. The stock has a fifty day moving average price of $14.29 and a two-hundred day moving average price of $16.69. Syndax Pharmaceuticals has a 52-week low of $12.06 and a 52-week high of $25.16.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Polar Asset Management Partners Inc. bought a new position in Syndax Pharmaceuticals in the fourth quarter valued at approximately $1,124,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Syndax Pharmaceuticals by 23.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 170,100 shares of the company’s stock valued at $2,249,000 after acquiring an additional 32,653 shares during the period. Voloridge Investment Management LLC bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $1,045,000. Soleus Capital Management L.P. increased its stake in shares of Syndax Pharmaceuticals by 128.4% during the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company’s stock worth $32,944,000 after purchasing an additional 1,401,016 shares during the last quarter. Finally, Twinbeech Capital LP raised its holdings in shares of Syndax Pharmaceuticals by 79.2% in the 4th quarter. Twinbeech Capital LP now owns 355,900 shares of the company’s stock valued at $4,705,000 after purchasing an additional 157,321 shares during the period.

Insider Buying and Selling

In other news, insider Neil Gallagher sold 4,618 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is owned by corporate insiders.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).